{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:30:19Z","timestamp":1792798219537,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001427","name":"All India Council for Technical Education","doi-asserted-by":"publisher","award":["1-6190129051"],"award-info":[{"award-number":["1-6190129051"]}],"id":[{"id":"10.13039\/501100001427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lfs.2021.119883","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T13:48:31Z","timestamp":1628689711000},"page":"119883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities"],"prefix":"10.1016","volume":"284","author":[{"given":"Amala","family":"Maxwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Ghate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesil","family":"Aranjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaila","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119883_bb0005","series-title":"Immunoass. Handb","first-page":"945","article-title":"Therapeutic drug monitoring (TDM)","author":"Routledge","year":"2013"},{"key":"10.1016\/j.lfs.2021.119883_bb0010","first-page":"1","article-title":"Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis","author":"Fujii","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.lfs.2021.119883_bb0015","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/open.201900193","article-title":"The supramolecular self-assembly of aminoglycoside antibiotics and their applications","volume":"8","author":"Jadhav","year":"2019","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.lfs.2021.119883_bb0020","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1126\/science.274.5291.1367","article-title":"Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic","volume":"274","author":"Fourmy","year":"1996","journal-title":"Science (80-.)"},{"key":"10.1016\/j.lfs.2021.119883_bb0025","first-page":"1","article-title":"Lipid-modified aminoglycosides for mRNA delivery to the liver","volume":"1901487","author":"Yu","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.lfs.2021.119883_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22122267","article-title":"Amikacin: uses, resistance, and prospects for inhibition","volume":"22","author":"Ramirez","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2021.119883_bb0035","first-page":"1","article-title":"Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis","author":"Wang","year":"2020","journal-title":"J. Matern. Neonatal. Med."},{"key":"10.1016\/j.lfs.2021.119883_bb0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity","volume":"27","author":"Kurt","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.lfs.2021.119883_bb0045","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/infdis\/135.Supplement_2.S249","article-title":"Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates","volume":"134","author":"Price","year":"1976","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119883_bb0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00007691-198503000-00003","article-title":"An overview of amikacin","volume":"7","author":"Ristuccia","year":"1985","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.lfs.2021.119883_bb0055","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1517\/13543776.2010.506189","article-title":"New aminoglycoside antibiotics","volume":"20","author":"Dozzo","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.lfs.2021.119883_bb0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijtb.2019.04.007","article-title":"Second-line injectable induced ototoxicity in drug resistant tuberculosis: a systematic review of Indian studies","volume":"66","author":"Sarin","year":"2019","journal-title":"Indian J. Tuberc."},{"key":"10.1016\/j.lfs.2021.119883_bb0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archinte.1989.00390030100019","article-title":"Analysis of amikacin-resistant Pseudomonas aeruginosa developing in patients receiving amikacin","volume":"149","author":"Maloney","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.lfs.2021.119883_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/13.suppl_A.1","article-title":"The key role of aminoglycosides in antibacterial therapy and prophylaxis","volume":"13","author":"Jackson","year":"1984","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/cb3005116","article-title":"Aminoglycoside antibiotics in the 21st century","volume":"8","author":"Becker","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.lfs.2021.119883_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drup.2010.08.003","article-title":"Aminoglycoside modifying enzymes","volume":"13","author":"Ramirez","year":"2010","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.lfs.2021.119883_bb0085","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.34.12.2381","article-title":"Appearance of amikacin and tobramycin resistance due to 4\u2019-aminoglycoside nucleotidyltransferase [ANT(4\u2019)-II] in gram-negative pathogens","volume":"34","author":"Jacoby","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0885066610377968","article-title":"Management of aminoglycosides in the intensive care unit","volume":"25","author":"Radigan","year":"2010","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.lfs.2021.119883_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/AAC.30.2.315","article-title":"Molecular cloning of amikacin resistance determinants from a Klebsiella pneumoniae plasmid","volume":"30","author":"Tolmansky","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0100","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2147\/IDR.S169271","article-title":"Efficacy of intraventricular amikacin treatment in pan-resistant pseudomonas aeruginosa postsurgical meningitis","volume":"11","author":"Molinaro","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.lfs.2021.119883_bb0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2017.01.002","article-title":"Intrathecal or intraventricular administration of colistin, vancomycin and amikacin for central nervous system infections in neurosurgical patients in an intensive care unit","volume":"49","author":"Tsimogianni","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2021.119883_bb0110","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1590\/S1413-86702008000600022","article-title":"Intrathecal use of amikacin: a case report","volume":"12","author":"Barrou","year":"2008","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119883_bb0115","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2146\/ajhp170632","article-title":"Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime\u2013avibactam and intrathecal amikacin","volume":"75","author":"Gofman","year":"2018","journal-title":"Am. J. Heal. Pharm."},{"key":"10.1016\/j.lfs.2021.119883_bb0120","first-page":"1","article-title":"An illustrated review about aminoglycosides","volume":"2","author":"Rahim","year":"2011","journal-title":"WebmedCentral Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119883_bb0125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/CMR.16.3.430-450.2003","article-title":"Versatility of aminoglycosides and prospects for their future","volume":"16","author":"Vakulenko","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.lfs.2021.119883_bb0130","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1128\/AAC.01032-15","article-title":"Optimizing the initial amikacin dosage in adults","volume":"59","author":"White","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.43.3.503","article-title":"Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey","volume":"43","author":"Fielding","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0140","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1128\/AAC.43.7.1737","article-title":"Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses","volume":"43","author":"Xiong","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0145","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1023\/A:1011925132473","article-title":"Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low clearance liposomes (MiKasome\u00ae)","volume":"15","author":"Fielding","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2021.119883_bb0150","unstructured":"AdisInsight Drugs, Amikacin liposomal - Gilead Sciences, (2000). https:\/\/adisinsight.springer.com\/drugs\/800003965."},{"key":"10.1016\/j.lfs.2021.119883_bb0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7326\/0003-4819-100-2-219","article-title":"Five-year surveillance of aminoglycoside usage in a university hospital","volume":"100","author":"Betts","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lfs.2021.119883_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(85)90184-6","article-title":"Aminoglycoside resistance in gram-negative bacilli during increased amikacin use","volume":"79","author":"Gerding","year":"1985","journal-title":"Am. J. Med."},{"key":"10.1016\/j.lfs.2021.119883_bb0165","series-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT) A Prospective, Open-label, Randomized Study","first-page":"1559","volume":"198","author":"Griffith","year":"2018"},{"key":"10.1016\/j.lfs.2021.119883_bb0170","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/17425247.2013.822860","article-title":"Liposomal antibiotics for the treatment of infectious diseases","volume":"10","author":"Alhariri","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.lfs.2021.119883_bb0175","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/IDR.S173867","article-title":"Antibiotic resistance: a rundown of a global crisis","volume":"11","author":"Aslam","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.lfs.2021.119883_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3201\/eid0901.020172","article-title":"Dead bugs don\u2019t mutate: susceptibility issues in the emergence of bacterial resistance","volume":"9","author":"Stratton","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119883_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/49.1.25","article-title":"Factors impacting on the problem of antibiotic resistance","volume":"49","author":"Levy","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.43.4.727","article-title":"Aminoglycosides: activity and resistance","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drup.2010.08.003","article-title":"Aminoglycoside modifying enzymes","volume":"13","author":"Ramirez","year":"2010","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.lfs.2021.119883_bb0200","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/AAC.32.9.1416","article-title":"Transposon-mediated amikacin resistance in Klebsiella pneumoniae","volume":"32","author":"Tolmasky","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0205","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1542\/peds.65.2.264","article-title":"Outbreak of amikacin-resistant enterobacteriaceae in an intensive care nursery","volume":"65","author":"Cook","year":"1980","journal-title":"Pediatrics"},{"key":"10.1016\/j.lfs.2021.119883_bb0210","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.01304-15","article-title":"Inhibition of AAC(6')-ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2',4'-bridged nucleic acid-NC-DNA hybrid oligomer","volume":"59","author":"Lopez","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0215","doi-asserted-by":"crossref","first-page":"13230","DOI":"10.1073\/pnas.0906529106","article-title":"Inhibition of aac(6')-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria","volume":"106","author":"Bistu\u00e9","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119883_bb0220","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/cbic.200700677","article-title":"NMR-guided fragment-based approach for the design of AAC(6')-lb ligands","volume":"9","author":"Lomb\u00e8s","year":"2008","journal-title":"ChemBioChem."},{"key":"10.1016\/j.lfs.2021.119883_bb0225","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/AAC.00129-14","article-title":"Inhibition of aminoglycoside 6'-N-acetyltransferase type ib by zinc: reversal of amikacin resistance in Acinetobacter baumannii and Escherichia coli by a zinc ionophore","volume":"58","author":"Lin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0230","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1128\/AAC.01106-15","article-title":"Inhibition of aminoglycoside 6'-N-acetyltransferase type ib-mediated amikacin resistance in Klebsiella pneumoniae by zinc and copper pyrithione","volume":"59","author":"Chiem","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0235","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jconrel.2017.07.032","article-title":"Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis","volume":"265","author":"Gonz\u00e1lez-V\u00e1zquez","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119883_bb0240","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/AJP.0b013e31816778f9","article-title":"Effect of microneedle design on pain in human volunteers","volume":"24","author":"Gill","year":"2008","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.lfs.2021.119883_bb0245","article-title":"Fear of injections and needle phobia among children and adolescents: an overview of psychological, behavioral, and contextual factors","volume":"4","author":"Orenius","year":"2018","journal-title":"SAGE Open Nurs."},{"key":"10.1016\/j.lfs.2021.119883_bb0250","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.2042-7158.1991.tb03534.x","article-title":"Improvement of ocular penetration of amikacin sulphate by association to Poly(butylcyanoacrylate) nanoparticles","volume":"43","author":"Losa","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119883_bb0255","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.tim.2019.07.004","article-title":"Nanoparticle-biofilm interactions: the role of the EPS matrix","volume":"27","author":"Fulaz","year":"2019","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.lfs.2021.119883_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/app8060845","article-title":"Treatment of biofilm communities: an update on new tools from the nanosized world","volume":"8","author":"Bertoglio","year":"2018","journal-title":"Appl. Sci."},{"key":"10.1016\/j.lfs.2021.119883_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.01153","article-title":"Nanoparticles in the treatment of infections caused by multidrug-resistant organisms","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119883_bb0270","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/AAC.01547-05","article-title":"Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa","volume":"50","author":"Mugabe","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0275","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/17425247.2013.822860","article-title":"Liposomal antibiotics for the treatment of infectious diseases","volume":"10","author":"Alhariri","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.lfs.2021.119883_bb0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/17518253.2020.1802517","article-title":"Detail review on chemical, physical and green synthesis, classification, characterizations and applications of nanoparticles","volume":"13","author":"Ijaz","year":"2020","journal-title":"Green Chem. Lett. Rev."},{"key":"10.1016\/j.lfs.2021.119883_bb0285","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","article-title":"Nanoparticles: properties, applications and toxicities","volume":"12","author":"Khan","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.lfs.2021.119883_bb0290","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.lfs.2021.119883_bb0295","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1126\/sciadv.aaz4316","article-title":"Nanoparticle elasticity regulates phagocytosis and cancer cell uptake","volume":"6","author":"Hui","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.lfs.2021.119883_bb0300","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.9b05679","article-title":"Overcoming the reticuloendothelial system barrier to drug delivery with a \u201cdon\u2019t-eat-us\u201d strategy","author":"Tang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.lfs.2021.119883_bb0305","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbamem.2009.06.022","article-title":"Nanoparticles evading the reticuloendothelial system: role of the supported bilayer","volume":"1788","author":"Li","year":"2009","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.lfs.2021.119883_bb0310","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.lfs.2021.119883_bb0315","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1021\/acs.accounts.8b00292","article-title":"Cellular uptake of nanoparticles versus small molecules: a matter of size","volume":"51","author":"Mosquera","year":"2018","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.lfs.2021.119883_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/s11671-018-2728-6","article-title":"Insight into cellular uptake and intracellular trafficking of nanoparticles","volume":"13","author":"Foroozandeh","year":"2018","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.lfs.2021.119883_bb0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijantimicag.2014.02.009","article-title":"Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections","volume":"43","author":"Abed","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2021.119883_bb0330","doi-asserted-by":"crossref","first-page":"14299","DOI":"10.1021\/acsami.7b15678","article-title":"Bacteria-targeting nanoparticles with microenvironment-responsive antibiotic release to eliminate intracellular Staphylococcus aureus and associated infection","volume":"10","author":"Yang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2021.119883_bb0335","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2147\/IJN.S27285","article-title":"Armstead, nanomedicine as an emerging approach against intracellular pathogens","volume":"6","author":"Li","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119883_bb0340","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0167-7799(00)01485-2","article-title":"Poloxamers and poloxamines in nanoparticle engineering and experimental medicine","volume":"18","author":"Moghimi","year":"2000","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.lfs.2021.119883_bb0345","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/coatings4010139","article-title":"Biomedical nanoparticles: overview of their surface immune-compatibility","volume":"4","author":"Gamucci","year":"2014","journal-title":"Coatings."},{"key":"10.1016\/j.lfs.2021.119883_bb0350","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/jphp.12481","article-title":"Polysorbate 80-coated PLGA nanoparticles improve the permeability of acetylpuerarin and enhance its brain-protective effects in rats","volume":"67","author":"Sun","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119883_bb0355","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF01644038","article-title":"Liposomes and nanoparticles as vehicles for antibiotics","volume":"19","author":"Kreuter","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.lfs.2021.119883_bb0360","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/408675","article-title":"Emerging technologies of polymeric nanoparticles in cancer drug delivery","volume":"2011","author":"Brewer","year":"2011","journal-title":"J. Nanomater."},{"key":"10.1016\/j.lfs.2021.119883_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163760","article-title":"Recent advances in polymeric nanoparticle-encapsulated drugs against intracellular infections","volume":"25","author":"S\u00e1nchez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2021.119883_bb0375","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.colsurfb.2018.05.028","article-title":"Polymeric nanoparticles as a platform for permeability enhancement of class III drug amikacin","volume":"169","author":"Fatima","year":"2018","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.lfs.2021.119883_bb0380","first-page":"96","article-title":"Optimization and designing of amikacin-loaded poly d, l-lactide-co-glycolide nanoparticles for effective and sustained drug delivery","volume":"11","author":"Fatima","year":"2019","journal-title":"J. Pharm. Bioallied Sci."},{"key":"10.1016\/j.lfs.2021.119883_bb0385","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1166\/jnn.2009.1090","article-title":"Thiolated chitosan nanoparticles as an oral delivery system for amikacin: in vitro and ex vivo evaluations","volume":"9","author":"Atyabi","year":"2009","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.lfs.2021.119883_bb0390","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119883_bb0395","first-page":"393","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) \u2013 structural investigations on two different carrier systems","volume":"15","author":"Saupe","year":"2005","journal-title":"Biomed. Mater. Eng."},{"key":"10.1016\/j.lfs.2021.119883_bb0400","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/026520499289185","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization","volume":"16","author":"Schwarz","year":"1999","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.lfs.2021.119883_bb0405","first-page":"35","article-title":"Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles","volume":"6","author":"Ghaffari","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119883_bb0410","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/136859","article-title":"Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery","volume":"2013","author":"Varshosaz","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2021.119883_bb0415","article-title":"Advances in liposomal drug delivery to cancer: an overview","volume":"56","author":"Saraf","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.lfs.2021.119883_bb0420","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1039\/C9TB02470K","article-title":"Development of functional liposomes by modification of stimuli-responsive materials and their biomedical applications","volume":"8","author":"Yuba","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.lfs.2021.119883_bb0425","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/17425247.2.1.75","article-title":"Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications","volume":"2","author":"Jaspart","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.lfs.2021.119883_bb0430","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.mayocp.2018.12.011","article-title":"Pharmacotherapy approaches in nontuberculous mycobacteria infections","volume":"94","author":"Shulha","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2021.119883_bb0435","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0924-8579(96)00003-9","article-title":"Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on gram-negative and gram-positive bacteria","volume":"7","author":"Omri","year":"1996","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2021.119883_bb0440","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.42.2.459","article-title":"Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection","volume":"42","author":"Leitzke","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0445","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/21691401.2017.1307209","article-title":"Enhancement of antimicrobial activity by liposomal oleic acid-loaded antibiotics for the treatment of multidrug-resistant Pseudomonas aeruginosa","volume":"46","author":"Pushparaj Selvadoss","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119883_bb0450","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1128\/AAC.32.9.1404","article-title":"Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice","volume":"32","author":"Duzgunes","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0455","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/17476348.2014.918507","article-title":"Inhaled liposomal amikacin","volume":"8","author":"Waters","year":"2014","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.lfs.2021.119883_bb0460","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0465","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17476348.2019.1638765","article-title":"Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches","volume":"13","author":"Kwon","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.lfs.2021.119883_bb0470","first-page":"1","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2021.119883_bb0475","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4014\/jmb.1506.06048","article-title":"Hydrogel dressing with a nano-formula against methicillin-resistant staphylococcus aureus and pseudomonas aeruginosa diabetic foot bacteria","volume":"26","author":"El-Naggar","year":"2015","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119883_bb0480","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ijbiomac.2020.03.248","article-title":"Bioinspired sodium alginate based thermosensitive hydrogel membranes for accelerated wound healing","volume":"155","author":"Abbasi","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.lfs.2021.119883_bb0485","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0163-7827(02)00004-8","article-title":"A lipid based depot (DepoFoam\u00ae technology) for sustained release drug delivery","volume":"41","author":"Mantripragada","year":"2002","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.lfs.2021.119883_bb0490","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1128\/AAC.39.8.1752","article-title":"Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice","volume":"39","author":"Roehrborn","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2021.119883_bb0495","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1369-7021(06)71389-X","article-title":"Electrospun nanofibers: solving global issues","volume":"9","author":"Ramakrishna","year":"2006","journal-title":"Mater. Today"},{"key":"10.1016\/j.lfs.2021.119883_bb0500","doi-asserted-by":"crossref","first-page":"56499","DOI":"10.1021\/acsami.0c18143","article-title":"Electrospun wrinkled porous polyimide nanofiber-based filter via thermally induced phase separation for efficient high-temperature PMs capture","volume":"12","author":"Xie","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2021.119883_bb0505","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1039\/D0TB00271B","article-title":"New forms of electrospun nanofiber materials for biomedical applications","volume":"8","author":"Chen","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.lfs.2021.119883_bb0510","doi-asserted-by":"crossref","first-page":"45673","DOI":"10.1021\/acsami.0c12410","article-title":"Advances in functional polymer nanofibers: from spinning fabrication techniques to recent biomedical applications","volume":"12","author":"Dos Santos","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2021.119883_bb0515","first-page":"130","article-title":"Electrospun nanofibers as a wound dressing for treating diabetic foot ulcer","volume":"14","author":"Liu","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119883_bb0520","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eurpolymj.2019.05.020","article-title":"Advancements in nanofibers for wound dressing: a review","volume":"117","author":"Ambekar","year":"2019","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.lfs.2021.119883_bb0525","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2016.02.003","article-title":"Daidzein-loaded nanostructured lipid carriers-PLGA nanofibers for transdermal delivery","volume":"501","author":"Song","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2021.119883_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nano10030486","article-title":"Physico-chemically distinct nanomaterials synthesized from derivates of a poly(Anhydride) diversify the spectrum of loadable antibiotics","volume":"10","author":"Mira","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.lfs.2021.119883_bb0535","series-title":"Phase II Studies of Nebulised Arikace in CF Patients With Pseudomonas aeruginosa Infection","first-page":"818","author":"Clancy","year":"2013"},{"key":"10.1016\/j.lfs.2021.119883_bb0540","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled liposomal antimicrobial delivery in lung infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2021.119883_bb0545","first-page":"290","article-title":"Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (Arikace) compared with TOBI\u00ae in cystic fibrosis patients with chronic infection due to pseudomonas aeruginosa (abstract)","volume":"48","author":"Bilton","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.lfs.2021.119883_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030110","article-title":"Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs","volume":"11","author":"He","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.lfs.2021.119883_bb0555","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1060028015621916","article-title":"New inhaled antimicrobial formulations for use in the cystic fibrosis patient population","volume":"50","author":"Campbell","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.lfs.2021.119883_bb0560","series-title":"Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease","first-page":"814","volume":"195","author":"Olivier","year":"2017"},{"key":"10.1016\/j.lfs.2021.119883_bb0565","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/DDDT.S146111","article-title":"The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults","volume":"14","author":"Khan","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2021.119883_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0108703","article-title":"Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection","volume":"9","author":"Rose","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119883_bb0575","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.2147\/IJN.S203330","article-title":"Synthesis and characterization of nanometer-sized liposomes for encapsulation and microrna transfer to breast cancer cells","volume":"14","author":"Lujan","year":"2019","journal-title":"Int. J. Nanomedicine"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521008705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521008705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:44:39Z","timestamp":1777423479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521008705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":114,"alternative-id":["S0024320521008705"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119883","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119883"}}